NOVO NORDISK A S

NVO · XNYS

CIK 353278fmd_1RZCXQKZ50S1QTDAKAVSQDHV9CManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2015 to Dec 31, 2025, 11 periods

Income Statement · Annual · Millions · DKK
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	111,780	111,696	111,831	122,021	126,946	140,800	176,954	232,261	290,403	309,064
Cost of revenue	17,183	17,632	17,617	20,088	20,932	23,658	28,448	35,765	44,522	58,788
Gross profit	94,597	94,064	94,214	101,933	106,014	117,142	148,506	196,496	245,881	250,276
Research and development	14,563	14,014	14,805	14,220	15,462	17,772	24,047	32,443	48,062	52,039
Operating income	48,432	48,967	47,248	52,483	54,126	58,644	74,809	102,574	128,339	127,658
Interest expense	726	1,533	1,755	3,995	2,624	2,451	5,986	845	7,346	6,778
Income before taxes	47,798	48,680	47,615	48,553	53,130	59,080	69,062	104,674	127,191	130,540
Income tax expense	9,873	10,550	8,987	9,602	10,992	11,323	13,537	20,991	26,203	28,106
Net income from continuing operations	37,925	38,130	38,628	38,951	42,138	47,757	55,525	83,683	100,988	102,434
Net income	37,925	38,130	38,628	38,951	42,138	47,757	55,525	83,683	100,988	102,434